Technical Analysis for PARDP - Poniard Pharm 2.4375 Pfd

Grade Last Price % Change Price Change
grade D 0.25 -28.57% -0.1000
PARDP closed down 28.57 percent on Thursday, October 3, 2019, on 1.54 times normal volume. The bears made the stock sink to a new 52-week low.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
See historical PARDP trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Gapped Down Weakness 0.00%
New 52 Week Closing Low Bearish -28.57%
Hot IPO Pullback Bullish Swing Setup -28.57%
Volume Surge Other -28.57%
Doji - Bullish? Reversal -28.57%
New 52 Week Low Weakness -28.57%
Older signals for PARDP ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.
Chemistry RTT Cancer Biopharmaceutical Chemical Compounds Solid Tumors Prostate Cancer Targeted Therapy Cancer Therapy Treating Cancer Metastatic Colorectal Cancer Cancer Therapeutics Pyridines Oncolytics Biotech Organochlorides Treatment Of Metastatic Colorectal Cancer

Is PARDP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News


Indicator Value
52 Week High 0.59
52 Week Low 0.25
Average Volume 1,622
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 0.4395
Average True Range 0.0000
ADX 0.0
+DI 0.0000
-DI 0.0000
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line 0.0000
MACD Signal Line 0.0000
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.2500
Resistance 3 (R3) 0.2500 0.2500 0.2500
Resistance 2 (R2) 0.2500 0.2500 0.2500 0.2500
Resistance 1 (R1) 0.2500 0.2500 0.2500 0.2500 0.2500
Pivot Point 0.2500 0.2500 0.2500 0.2500 0.2500
Support 1 (S1) 0.2500 0.2500 0.2500 0.2500 0.2500
Support 2 (S2) 0.2500 0.2500 0.2500 0.2500
Support 3 (S3) 0.2500 0.2500 0.2500
Support 4 (S4) 0.2500